ANTIHISTAMINE TUMOR-PROMOTION EPIDEMIOLOGY STUDIES UNDER CONSIDERATION
This article was originally published in The Tan Sheet
Executive Summary
ANTIHISTAMINE TUMOR-PROMOTION EPIDEMIOLOGY STUDIES UNDER CONSIDERATION by FDA in response to a study published in the May 18 Journal of the National Cancer Institute that found that three prescription antihistamines -- Schering-Plough's Claritin (loratadine), Janssen's Hismanal (astemizole) and Pfizer's Atarax (hydroxyzine) -- stimulate the growth of tumors in mice. In a May 17 "Talk Paper," FDA said it "is evaluating the feasibility of epidemiologic studies in patients with cancer."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning